Registration
SIDLEY AUSTIN LLP for GW PHARMA INC.
Firm
Client
Income
—
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDA and DEA regulation of cannabidiol; support of and technical changes to S. 481 (Improving Regulatory Transparency for New Medical Therapies Act); S. 1333 (Therapeutic Hemp Medical Access Act of 2015)
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICIA LOUISE DELOATCHE New | Health Policy Director, Sen. Orrin Hatch; Chief of Staff, Legislative Director, and Legislative Assistant for Rep. Mike Bilirakis |
| PETER M GOODLOE New | — |
| DORA HUGHES New | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| GW PHARMA PLC | United Kingdom | United Kingdom | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.